PMID- 27909617
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2149-3235 (Print)
IS  - 2149-3057 (Electronic)
IS  - 2149-3235 (Linking)
VI  - 42
IP  - 4
DP  - 2016 Dec
TI  - Diagnostic value of microRNAs in prostate cancer patients with prostate specific 
      antigen (PSA) levels between 2, and 10 ng/mL.
PG  - 247-255
AB  - OBJECTIVE: Prostate specific antigen (PSA), used for the early diagnosis of 
      prostate cancer (PCa), is one of the best tumour markers known so far. However, 
      in situations when PSA is between 2-10 ng/mL, which is named as grey zone, PSA 
      falls short of distinguishing benign prostate diseases from PCa. On the other 
      hand, it was demonstrated in many previous studies that microRNA (miRNA) could be 
      a marker for cancer. Therefore, in this study, it was aimed to enhance the 
      diagnostic power of PSA, especially with grey zone patients, by the use of miRNA. 
      MATERIAL AND METHODS: Ninety-four patients included in the study were divided 
      into three groups as "control group" (n=44, PSA=2-10 ng/mL and benign), "PCa 1 
      group" (n=37, PSA=2-10 ng/mL), and "PCa 2 group" (n=13, PSA >10 ng/mL), according 
      to their pathological results and PSA levels. Free PSA (fPSA) and total PSA 
      (T-PSA) levels were measured with chemiluminometric sandwich immunoassay method. 
      Expressions of miRNAs were analyzed using quantitative reverse 
      transcription-polymerase chain reaction (qRT-PCR) method. The most appropriate 
      specificity, sensitivity and prediction values were found by drawing the receiver 
      operating characteristic (ROC) curves of total PSA, free/total PSA (f/T PSA) 
      ratio, and miRNAs, and the diagnostic powers were compared with each other. 
      RESULTS: Diagnostic powers of the f/T PSA ratio and miRNA were compared in PCa 1 
      and the control groups to determine the marker with higher area under the curve 
      (AUC). It was shown that the diagnostic power of the combination of miR-16-5p and 
      f/T PSA was higher than that obtained when they were used separately. CONCLUSION: 
      As a result, while making the the discrimination between benign and malignant 
      prostate in patients with grey zone, it was determined that the combination of 
      miR-16-5p and f/T PSA was more valuable than T-PSA or f/T PSA alone. It was 
      thought that diagnostic role of miRNAs in the early diagnosis of the different 
      stages of PCa needed to be examined in further studies with larger groups.
FAU - Akbayir, Serin
AU  - Akbayir S
AD  - Karaman State Hospital, Biochemistry Laboratory, Karaman, Turkey.
FAU - Muslu, Necati
AU  - Muslu N
AD  - Department of Biochemistry, Mersin University School of Medicine, Mersin, Turkey.
FAU - Erden, Sema
AU  - Erden S
AD  - Mersin University, Vocational School of Health Services, Mersin, Turkey.
FAU - Bozlu, Murat
AU  - Bozlu M
AD  - Department of Urology, Mersin University School of Medicine, Mersin, Turkey.
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Turk J Urol
JT  - Turkish journal of urology
JID - 101643563
PMC - PMC5125738
OTO - NOTNLM
OT  - Grey zone
OT  - marker
OT  - microRNA
OT  - prostate cancer
COIS- No conflict of interest was declared by the authors.
EDAT- 2016/12/03 06:00
MHDA- 2016/12/03 06:01
PMCR- 2016/12/01
CRDT- 2016/12/03 06:00
PHST- 2016/12/03 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2016/12/03 06:01 [medline]
PHST- 2016/12/01 00:00 [pmc-release]
AID - tju-42-4-247 [pii]
AID - 10.5152/tud.2016.52463 [doi]
PST - ppublish
SO  - Turk J Urol. 2016 Dec;42(4):247-255. doi: 10.5152/tud.2016.52463.